Game-Changing Evolve Formulas Products Soon to Disrupt the Oregon Cannabis Market
—NanoSphere Health Sciences Signs Letter of Intent with Cascade Pure—
NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF), the biotechnology leader behind the patented NanoSphere Delivery
System™, today signed a new letter of intent with
Cascade Pure, LLC, which will bring
Evolve Formulas products to the Oregon medical and recreational cannabis markets. The brand’s pioneering product, the Evolve
Formulas Transdermal NanoSerum™, will hit dispensary shelves in the first quarter of 2019.
“Coming on the heels of Evolve Formulas’ California debut, we are eager to continue our west coast expansion by entering Oregon,
with additional markets soon to follow,” said Robert Sutton, Chairman and CEO of NanoSphere Health Sciences and Evolve Formulas.
“Cascade Pure shares NanoSphere’s mission to bring revolutionary solutions to the cannabis industry from seed to sale, making them
an ideal partner fit. Together, we will drive innovation and set a new precedent for quality, safety and precision in
cannabis-infused products.”
“Nanotechnology is the future of cannabis, and NanoSphere Health Sciences has mastered the art with its industry-leading
NanoSphere Delivery System™,” said Cascade Pure Co-Founder and CEO Edward Bonn. “We are proud to break ground with NanoSphere and
foster Evolve Formulas’ growth in a new market of consumers looking for a unique, discreet and approachable option that provides
unparalleled relief.”
Cascade Pure, LLC will provide a state-of-the-art cultivation and processing facility located in Bend, Oregon. Their conceptual
plan is designed around the
Smart Grow Systems solutions, and will be modified to fit NanoSphere’s needs. Their proprietary building system revolutionizes
indoor cultivation and processing facilities. NanoSphere plans to take this partnership into additional markets in the future.
Cascade Pure, LLC is an Oregon-based company formed to operate the production of genetically superior, pathogen and bug-free
clones as well as a seed bank second to none, utilizing tissue culture technology. Cascade Pure offers over 800+ strains of rare,
high value and in-demand stains. It also has the ability to offer limited exclusive genetic strains to preferred customers. Evolve
Formulas will be the sole brand that Cascade Pure distributes.
For more information on NanoSphere Health Sciences, Inc. or to schedule an interview, please contact Gabrielle Wesseldyk at
media@nanospherehealth.com or 212-255-0945.
NanoSphere’s Commitment to Licensing IP
NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous
evaluation process. For more information about NanoSphere’s licensing program, please visit:
https://www.nanospherehealth.com/licensing/
About NanoSphere
NanoSphere Health Sciences, Inc. is a biotechnology firm specializing in the creation of the patented NanoSphere Delivery
System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter
medications for the cannabis, pharmaceutical and animal health industries, and beyond. Covered by U.S. Patent No. 10,028,919 and
U.S. Patent No. 9,925,149, NanoSphere Delivery System™ represents one of the most important developments for advancing the
non-invasive and user-friendly delivery of biological agents in over 25 years. NanoSphere was awarded the 2018 Frost and Sullivan
Technology Innovation Award and was recognized by ACQ5 Global Awards as Company of the Year for Nano-Biotechnology, Innovative
Company of the Year for Healthcare, and its CEO Robert Sutton was honored as Gamechanger of the Year. For more information on
NanoSphere, please visit
http://www.nanospherehealth.com.
About Evolve Formulas
Evolve Formulas is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis.
Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with
nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and
intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing.
Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™
is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications
for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit
https://www.evolveformulas.com/. Follow us on
Facebook,
Instagram and
Twitter.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in
this news release which are not purely historical are forward looking statements, including without limitation any statements
concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes
that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking
statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without
limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be
assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from
those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and
uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the
date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons
why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new
information, future events or otherwise.
For NanoSphere Health Sciences, Inc.
Gabrielle Wesseldyk, 212-255-0945
gabrielle@rosengrouppr.com
or
On behalf of the Board
Robert Sutton, Office: 720-520-4282
Chairman and CEO
rsutton@nanospherehealth.com
or
Investors:
Victor Goncalves, Mobile: 204-997-5517
Executive Vice President
vgoncalves@nanospherehealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181113005345/en/